ENZA-p试验方案:以PSMA为治疗靶点与预后指标的随机II期试验
ENZA-p(ANZUP 1901)是一项开放标签、随机、两臂、多中心II期试验,纳入有早期进展高风险的转移性去势抵抗性前列腺癌(mCRPC)患者,随机接受恩扎卢胺单药或恩扎卢胺联合177Lu-PSMA-617治疗,主要终点为PSA无进展生存期(PFS),计划入组160例。
要点
- 恩扎卢胺联合177Lu-PSMA-617可能具有协同作用。
- 主要终点为PSA-PFS,次要终点包括影像学PFS、PSA缓解率、总生存等。
- 关键入组标准包括68Ga-PSMA PET阳性且≥2项早期恩扎卢胺失败高风险特征。
核心结论
- 177Lu-PSMA-617与恩扎卢胺联合可能具有协同作用,ENZA-p将确定该联合方案的安全性和有效性,并开发预测和预后生物标志物以更好地指导治疗决策。
研究设计与样本
- ENZA-p(ANZUP 1901)是一项开放标签、随机、两臂、多中心II期试验,参与者按1:1随机分配至恩扎卢胺160 mg每日单药组或恩扎卢胺联合177Lu-PSMA-617 7.5 GBq(第15天和第57天)组。
- 允许根据第92天68Ga-PSMA PET结果额外给予两剂177Lu-PSMA-617(总共最多四剂)。
- 计划入组160例参与者,提供80%把握度,双侧1型错误率5%,以检测风险比0.625,假设恩扎卢胺单药中位PSA-PFS为5个月。
关键数值与推荐
- 关键 eligibility 标准包括:生化 and/or 临床进展;68Ga-PSMA PET avid 疾病;无 prior androgen signalling inhibitor(除阿比特龙外);无 prior chemotherapy for mCRPC;≥2项 early enzalutamide failure 高风险特征。
- 主要终点为前列腺特异性抗原(PSA)无进展生存期(PFS)。
- 其他主要终点包括影像学PFS、PSA缓解率、总生存、健康相关生活质量、不良事件和成本效益。
临床怎么用
- 评估恩扎卢胺联合177Lu-PSMA-617在mCRPC患者中的疗效和安全性,并探索影像、血液和组织中的预后和预测生物标志物。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To determine the activity and safety of lutetium-177 (177 Lu)-prostate-specific membrane antigen (PSMA)-617 in men with metastatic castration-resistant prostate cancer (mCRPC) commencing enzalutamide, who are at high risk of early progression, and to identify potential prognostic and predictive biomarkers from imaging, blood and tissue. PARTICIPANTS AND METHODS: ENZA-p (ANZUP 1901) is an open-label, randomized, two-arm, multicentre, phase 2 trial. Participants are randomly assigned (1:1) to treatment with enzalutamide 160 mg daily alone or enzalutamide plus 177 Lu-PSMA-617 7.5 GBq on Days 15 and 57. Two additional 177 Lu-PSMA-617 doses are allowed, informed by Day-92 Gallium-68 (68 Ga)-PSMA positron emission tomography (PET; up to four doses in total). The primary endpoint is prostate-specific antigen (PSA) progression-free survival (PFS). Other major endpoints include radiological PFS, PSA response rate, overall survival, health-related quality of life, adverse events and cost-effectiveness. Key eligibility criteria include: biochemical and/or clinical progression; 68 Ga-PSMA PET-avid disease; no prior androgen signalling inhibitor, excepting abiraterone; no prior chemotherapy for mCRPC; and ≥2 high-risk features for early enzalutamide failure. Assessments are 4 weekly during study treatment, then 6 weekly until radiographic progression. Response Evaluation Criteria in Solid Tumours (RECIST) are used to assess imaging conducted every 12 weeks, 68 Ga-PSMA PET at baseline, Days 15 and 92, and at progression, and 18 F-fluorine deoxyglucose (18 F-FDG) PET at baseline and progression. Translational samples include blood (and optional biopsies) at baseline, Day 92, and first progression. Correlative studies include identification of prognostic and predictive biomarkers from 68 Ga-PSMA and 18 F-FDG PET/CT, circulating tumour cells and circulating tumour DNA. The trial will enrol 160 participants, providing 80% power with a two-sided type-1 error rate of 5% to detect a hazard ratio of 0.625 assuming a median PSA-PFS of 5 months with enzalutamide alone. RESULTS AND CONCLUSION: The combination of 177 Lu-PSMA-617 and enzalutamide may be synergistic. ENZA-p will determine the safety and efficacy of the combination in addition to developing predictive and prognostic biomarkers to better guide treatment decisions.
引用
- Emmett L, Subramaniam S, Joshua AM, et al. ENZA-p trial protocol: a randomized phase II trial using prostate-specific membrane antigen as a therapeutic target and prognostic indicator in men with metastatic castration-resistant prostate cancer treated with enzalutamide (ANZUP 1901). BJU Int. 2021. PMID: 34028967. doi:10.1111/bju.15491
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。